Phase 3 study of first-line crizotinib vs pemetrexed−cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).
2016 ◽
Vol 34
(15_suppl)
◽
pp. 9058-9058
◽
Keyword(s):
Phase 3
◽